Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BL-M07D1 in HER2-positive or HER2-low advanced solid tumors of the urinary and digestive systems
CTR20232779Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M07D1, sponsored by Biokin Pharmaceutical. Started Feb 2024; status: active.
02
Drugs
BL-M07D1
Beyond the preview
Go deeper on CTR20232779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232779.